Philogen licenses autoimmune disease drug to Pfizer

01/4/2013 | Reuters

Pfizer secured exclusive, worldwide rights to develop and market Philogen's Dekavil, an investigational drug for autoimmune diseases. Dekavil is an early-stage antibody that targets inflammatory disease sites. The deal entitles Philogen to an an upfront fee and potential milestone fees and royalties.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA